Compare Advance Auto Parts, Inc. (AAP) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Citius Pharmaceuticals Inc — how do they compare? Advance Auto Parts, Inc. trades at $53.47 (market cap $3.19B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: Advance Auto Parts, Inc. is far larger — about 159.4× Citius Pharmaceuticals Inc's market cap, and Advance Auto Parts, Inc. pays a 1.89% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AAP | CTXR | |
|---|---|---|
Market Cap | $3.19B | $20.01M |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $1.82 |
52-Week Low | $38.75 | $0.48 |
Enterprise Value | $5.47B | $16.23M |
Dividend Yield | 1.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $53.59, down 3.84% on the day, with a bearish technical signal. Recent earnings have consistently beaten estimates, but profitability remains thin with a net margin of 0.51%. The company is executing a turnaround focused on professional sales and supply chain restructuring. Cash flow trends show heavy financing activity supporting operations.
The outlook is mixed; analyst consensus is a Buy with a $61.30 price target, but high debt and weak operating cash flow pose risks. Upside depends on successful execution of the restructuring plan to improve margins and stabilize revenue. Near-term support is at $52, with resistance at $55.
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
